Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection

被引:29
|
作者
Alain, S
Hantz, S
Scieux, C
Karras, A
Mazeron, MC
Szelag, JC
Imbert, BM
Fillet, AM
Gouarin, S
Mengelle, C
de Wilde, A
Cogne, N
Champier, G
Rogez, S
Legendre, C
Denise, F
机构
[1] Teaching Hosp Dupuytren, Dept Bacteriol Virol Hyg, EA, Limoges, France
[2] Teaching Hosp St Louis, Dept Nephrol, Paris, France
[3] Teaching Hosp St Louis, Dept Bacteriol Virol, Paris, France
[4] Teaching Hosp Lariboisiere, Dept Bacteriol Virol, Paris, France
[5] Teaching Hosp Dupuytren, Dept Nephrol, Limoges, France
[6] Teaching Hosp, Dept Virol, Nantes, France
[7] Teaching Hosp Pitie Salpetriere, Dept Virol, Paris, France
[8] Teaching Hosp Caen, Caen, France
[9] Teaching Hosp Purpan, Dept Virol, Toulouse, France
[10] Teaching Hosp Lille, Dept Virol, Lille, France
关键词
human cytomegalovirus; ganciclovir resistance; valaciclovir transplantation;
D O I
10.1002/jmv.20127
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Whether valaciclovir(VCV) prophylaxis could be responsible for ganciclovir (GCV)-resistance of Human cytomegalovirus (HCMV) in transplantation has never been documented. A multicentric retrospective pilot study was undertaken to detect GCV-resistance through mutations within the UL97 gene in renal transplant recipients who experienced active HCMV infection and received valacyclovir prophylaxis. Twenty-three patients who experienced HCMV antigenaemia or DNAemia during or at the end of prophylaxis were included. UL97 genotyping was carried out on peripheral blood samples, using a nested in-house PCR, which amplified the full-length UL97 gene. One patient has a resistance-related mutation (M4601); the major risk factor for emergence of resistance in this patient was the presence of early and persistent antigenaemia. GCV-resistance during VCV-prophylaxis was rare after renal transplantation. However, special attention must be paid to patients developing early active HCMV infection under prophylaxis. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:566 / 573
页数:8
相关论文
共 50 条
  • [1] Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir
    Zhang, P.
    Wang, W.
    Zhang, L.
    Li, S. F.
    Guam, L. B.
    Dong, L. Q.
    Zhou, S.
    Yu, P.
    ACTA VIROLOGICA, 2013, 57 (03) : 375 - 377
  • [2] A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients
    Pavlopoulou, ID
    Syriopoulou, VP
    Chelioti, H
    Daikos, GL
    Stamatiades, D
    Kostakis, A
    Boletis, JN
    CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (09) : 736 - 743
  • [3] Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients
    Israni, A
    Krok, K
    Cohen, D
    Blumberg, E
    Bloom, RD
    TRANSPLANTATION PROCEEDINGS, 2004, 36 (10) : 3019 - 3024
  • [4] Evaluation of Ganciclovir Resistance in Cytomegalovirus Infection of Renal Transplant Recipients in Tehran
    Hosseini, S. M. Javad
    Nemati, E.
    Behzadian, F.
    Einollahi, B.
    Petrudy, A. Rahimi
    Sohraby, M.
    Taghipour, M.
    Motalebi, M.
    TRANSPLANTATION PROCEEDINGS, 2015, 47 (04) : 1140 - 1142
  • [5] IS THE VALACYCLOVIR PROPHYLAXIS EFFECTIVE FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS?
    Park, Woo Yeong
    Yeo, Sang Mok
    Park, Hayeon
    Kang, Seong Sik
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    TRANSPLANT INTERNATIONAL, 2017, 30 : 490 - 490
  • [6] IS THE VALACYCLOVIR PROPHYLAXIS EFFECTIVE FOR PREVENTION OF CYTOMEGALOVIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS?
    Park, Woo Yeong
    Kang, Seong Sik
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 418 - 418
  • [7] Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk.
    Velioglu, A.
    Arikan, H.
    Asicioglu, E.
    Alagoz, S.
    Seyahi, N.
    Tuglular, S.
    Ozener, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 829 - 830
  • [8] PROPHYLAXIS WITH GANCICLOVIR OF CYTOMEGALOVIRUS-INFECTION IN KIDNEY-TRANSPLANT RECIPIENTS
    RONDEAU, E
    BOURGEON, B
    PERALDI, MN
    LANG, P
    BUISSON, C
    SCHULTE, KM
    WEILL, B
    SRAER, JD
    PRESSE MEDICALE, 1992, 21 (41): : 1979 - 1980
  • [9] Lymphocyte Function during Valacyclovir and Valganciclovir Cytomegalovirus Prophylaxis in Renal Transplant Recipients
    Reischig, Tomas
    Prucha, Miroslav
    Sedlackova, Lenka
    Jindra, Pavel
    Bouda, Mirko
    Matejovic, Martin
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 143 - 143
  • [10] Prophylaxis of cytomegalovirus (CMV) disease in high-risk renal transplant recipients. A randomized comparison of valacyclovir with oral ganciclovir
    不详
    KIDNEY & BLOOD PRESSURE RESEARCH, 2005, 28 (02): : 98 - 98